In conclusion, due to the structural formulation and technological characteristics, which confer a high and proven safety profile, SLNs could represent an excellent strategy for the administration of N/OFQ, nominating them as potential regulators of AHR and bronchial inflammation in inflammatory airway diseases, offering an additional approach to the treatment of asthma. Here, AHR is linked to asthma.